The $122million Series B raise by CREATE Medicines underscores the growing commercial imperative for advanced cell therapy platforms in addressing unmet medical needs in the Middle East and North Africa (MENA) region. The company’s in vivo CAR T technology, which enables simultaneous programming of T cells, natural killer cells, and myeloid cells, represents a paradigm shift in oncology and autoimmune treatment. For the MENA market—a region increasingly prioritizing innovative healthcare solutions due to rising chronic disease burdens and aging populations—CREATE’s platform offers a scalable model that could reduce reliance on imported therapies, thereby enhancing local healthcare autonomy. The commercial potential is amplified by the region’s expanding private healthcare sector and government initiatives to bolster biotech manufacturing capabilities. However, CREATE’s competition with established players like Eli Lilly and Gilead—both of whom have aggressively pursued CAR T investments—highlights the need for strategic differentiation. Sovereign entities in the MENA region, such as Saudi Arabia’s Public Investment Fund or the UAE’s healthcare modernization programs, may view such breakthroughs as opportunities to diversify sovereign capital away from traditional energy sectors into high-growth life sciences, potentially catalyzing regional R&D hubs.
The infusion of venture capital into CREATE Medicines reflects broader trends in MENA’s healthtech ecosystem, where investors are increasingly channeling resources into next-generation therapies with high innovation potential. The $122 million round, backed by strategic investors likely including regional or global venture firms, signals confidence in in vivo CAR T approaches as a viable alternative to the ex vivo models that dominated earlier stages of the space. This aligns with MENA venture capital’s shift toward biotech and precision medicine, driven by both local market demands and access to global capital networks. Notably, CREATE’s focus on refractory autoimmune conditions—such as those targeting CD19—and its dual-targeting CD19/BCMA program could resonate strongly in the region, where autoimmune diseases like lupus and rheumatoid arthritis are prevalent. However, translating these therapies to MENA markets will require navigating regulatory landscapes and addressing disparities in healthcare access, which may necessitate public-private partnerships to ensure equitable adoption and cost management.
The technical complexity of CREATE’s mRNA-based platform and its application to in vivo therapy development underscores the critical role of regional infrastructure in scaling such innovations. For MENA countries aiming to position themselves as hubs for advanced medical research, this development highlights the urgency of investing in state-of-the-art laboratories, bio-manufacturing facilities, and clinical trial networks. The success of CREATE’s MT-303 program, which demonstrates a “compelling response profile” in hepatocellular carcinoma—a cancer type with significant incidence in parts of the MENA region—could drive demand for localized clinical expertise and manufacturing partnerships. This, in turn, may pressure governments to accelerate infrastructure projects aligned with global health-tech standards. Yet, the high R&D costs and regulatory hurdles associated with in vivo CAR T therapies could strain public budgets unless supplemented by sovereign capital or international funding mechanisms. The interplay between venture capital’s agility and sovereign capital’s scale will be pivotal in determining whether MENA can transition from a consumer of biotech advancements to a contributor to global innovation in this domain.
CREATE Medicines’ funding round is emblematic of the convergence of technology and healthcare in the MENA region, where both venture capital and sovereign actors are recalibrating their strategies to capitalize on biotech opportunities. The company’s mRNA platform, which distinguishes it from larger competitors reliant on traditional viral vectors, aligns with a global shift toward mRNA-based therapies—an area where MENA’s tech-savvy startup scene and growing digital infrastructure could play a complementary role. However, the region’s ability to fully leverage such innovations will depend on its capacity to cultivate technical talent, secure intellectual property-friendly frameworks, and integrate cutting-edge therapies into existing healthcare systems. For sovereign entities, this presents a strategic tease: whether to directly invest in companies like CREATE or foster ecosystems that enable local replication of such breakthroughs. The outcome will have profound implications for the region’s position in the global life sciences value chain, particularly as CAR T therapies expand beyond niche indications to become mainstream treatments.
